PYXS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PYXS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Pyxis Oncology has the GF Value Rank of 0.
The GF Value Rank is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.
GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).
We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.
After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Thank you for viewing the detailed overview of Pyxis Oncology's GF Value Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Pamela Ann Connealy | officer: Chief Financial Officer | 320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016 |
Jitendra Wadhane | officer: Chief Accounting Officer | 35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140 |
Lara Sullivan | director, officer: Chief Executive Officer | C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD, SUITE 455, ROCKVILLE MD 20850 |
Jakob Dupont | director | C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063 |
Pfizer Inc | 10 percent owner | 66 HUDSON BOULEVARD EAST, NEW YORK NY 10001-2192 |
Pfizer Ventures (us) Llc | 10 percent owner | 66 HUDSON BOULEVARD EAST, NEW YORK NY 10001-2192 |
Rachel Humphrey | director | C/O MIRATI THERAPEUTICS INC., 4660 LA JOLLA VILLAGE DRIVE, SUITE 500, SAN DIEGO CA 92121 |
Plc Barclays | 10 percent owner | 1 CHURCHILL PLACE, CANARY WHARF, LONDON X0 E14 5HP |
Mark Chin | other: Former Director | 20 BERKELEY SQUARE, MAYFAIR, LONDON X0 W1J 6EQ |
Darren S Cline | director | 35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140 |
Thomas Civik | director | C/O FOUNDATION MEDICINE, INC., 150 SECOND STREET, CAMBRIDGE MA 02141 |
Cormorant Asset Management, Lp | 10 percent owner | 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116 |
Bayer World Investments B.v. | 10 percent owner | ENERGIEWEG 1, MIJDRECHT P7 3641 |
Freda C Lewis-hall | director | C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139 |
Ronald Herbst | officer: Chief Scientific Officer | 35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 06-22-2022
By sperokesalga sperokesalga • 05-24-2023
By GuruFocusNews GuruFocusNews • 06-28-2022
By sperokesalga sperokesalga • 05-30-2023
By Marketwired • 09-27-2023
By GuruFocus Research • 09-14-2023
By PurpleRose PurpleRose • 08-15-2022
By GlobeNewswire • 12-29-2023
By Marketwired • 06-30-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.